zolbetuximab
astellas
[]
the #oncoalerttoptweet for day1 #gi23 tweet practice-changing
zolbetuximab + mfolfox6 meets1 ry endpoint in spotlight trial improves pfs, os in pts w/ cldn18.2+, her2-negative, locally adv unresectable/met gastric/gej cancer best, 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨